Search results
Results from the WOW.Com Content Network
Insulin glargine sold under the brand name Lantus among others is a long-acting modified form of medical insulin, used in the management of type 1 and type 2 diabetes. [7] It is injected just under the skin . [ 7 ]
Package inserts for prescription drugs often include a separate document called a "patient package insert" with information written in plain language intended for the end-user—the person who will take the drug or give the drug to another person, such as a minor. Inserts for over-the-counter medications are also written plainly. [1] [2]
Slow-acting insulin such as Lantus or Levemir can be used for a large portion of the basal insulin needs, and the pump basal rate program can be used to fill in the remaining need. Lantus injected once daily is one back-up for pump users, but it can be a real benefit for some insulin pumpers who tend to develop ketoacidosis quickly. [citation ...
As a medication, insulin is any pharmaceutical preparation of the protein hormone insulin that is used to treat high blood glucose. [6] Such conditions include type 1 diabetes, type 2 diabetes, gestational diabetes, and complications of diabetes such as diabetic ketoacidosis and hyperosmolar hyperglycemic states. [6]
Donald Trump's proposed tariffs on Canada could increase U.S. gas prices by up to 70 cents a gallon, energy experts say.
It'll take more than stars to advance in the College Football Playoff. A look at the X-factors that could be critical in the first round.
If you suspect child abuse, call the Childhelp National Child Abuse Hotline at 1-800-4-A-Child or 1-800-422-4453, or go to www.childhelp.org. All calls are toll-free and confidential. The hotline ...
Insulin glargine/lixisenatide is approved as a prescription for adults with type 2 diabetes mellitus poorly controlled by lixisenatide or basal insulin alone. [6] According to the American Diabetes Association, combination treatment of a GLP-1 receptor agonist with basal insulin should occur after HbA1C levels remain above target (7% for most type 2 people with diabetes) following use of basal ...